再生元制药- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于再生元制药公司

Regeneron Pharmaceuticals, Inc. 是一家综合性生物技术公司。该公司发明、开发、制造和销售用于治疗严重疾病的药物。其产品和正在开发的产品候选物旨在帮助患有眼部疾病、过敏和炎症性疾病、癌症、心血管和代谢疾病、神经系统疾病、血液病、传染病和罕见疾病的患者。该公司通过其 VelociSuite 技术（例如 VelocImmune，它使用基因人源化小鼠生产优化的全人抗体和双特异性抗体）以及通过 Regeneron Genetics Center 等雄心勃勃的研究计划，帮助加速和改进传统的药物开发流程。其上市产品包括 EYLEA（阿柏西普）注射液；Dupixent（dupilumab）注射液；Libtayo（cemiplimab）注射液；Praluent（alirocumab）注射液；Kevzara（sarilumab）注射液等。

公司简介

公司代码REGN

公司名称Regeneron Pharmaceuticals Inc

上市日期Apr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

员工数量15106

证券类型Ordinary Share

年结日Apr 02

公司地址777 Old Saw Mill River Road

城市TARRYTOWN

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编10591

电话17813705000

网址https://www.regeneron.com/

公司代码REGN

上市日期Apr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

19.75K

+20.78%

Mr. Arthur F. (Art) Ryan

Independent Director

17.66K

-0.10%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.37K

+9.94%

Dr. Michael S. Brown, M.D.

Independent Director

12.62K

-0.13%

名称

名称/职务

职务

持股

持股变动

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Sanofi

1.18B

39.07%

EYLEA

736.00M

24.30%

Bayer

343.90M

11.35%

EYLEA HD

306.80M

10.13%

Libtayo

192.50M

6.36%

其他

266.30M

8.79%

暂无数据

业务

地区

业务USD

名称

营收

占比

Sanofi

1.18B

39.07%

EYLEA

736.00M

24.30%

Bayer

343.90M

11.35%

EYLEA HD

306.80M

10.13%

Libtayo

192.50M

6.36%

其他

266.30M

8.79%

股东统计

更新时间: 8月30日周六

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.44%

State Street Global Advisors (US)

4.64%

Dodge & Cox

3.67%

Fidelity Management & Research Company LLC

3.13%

其他

74.12%

持股股东

占比

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.44%

State Street Global Advisors (US)

4.64%

Dodge & Cox

3.67%

Fidelity Management & Research Company LLC

3.13%

其他

74.12%

股东类型

持股股东

占比

Investment Advisor

47.67%

Investment Advisor/Hedge Fund

28.51%

Hedge Fund

5.34%

Research Firm

2.70%

Pension Fund

2.54%

Bank and Trust

2.15%

Individual Investor

2.01%

Sovereign Wealth Fund

1.22%

Insurance Company

0.08%

其他

7.78%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

2023Q1

2366

99.66M

92.70%

-1.10M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

9.36M

8.81%

+117.55K

+1.27%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.74M

5.41%

+45.93K

+0.81%

Mar 31, 2025

State Street Global Advisors (US)

4.79M

4.51%

-42.58K

-0.88%

Mar 31, 2025

Dodge & Cox

2.32M

2.19%

+2.77K

+0.12%

Mar 31, 2025

Fidelity Management & Research Company LLC

7.40M

6.97%

-573.19K

-7.19%

Mar 31, 2025

Capital International Investors

3.99M

3.76%

-747.80K

-15.79%

Mar 31, 2025

JP Morgan Asset Management

4.08M

3.84%

-1.16M

-22.19%

Mar 31, 2025

Geode Capital Management, L.L.C.

2.47M

2.33%

+41.95K

+1.73%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

2.19M

2.07%

-36.81K

-1.65%

Jun 30, 2025

Putnam Investment Management, L.L.C.

1.91M

1.8%

+285.04K

+17.50%

Mar 31, 2025

持股ETF

更新时间: 9月6日周六

机构名称

占比

Amplify Weight Loss Drug & Treatment ETF

7.43%

Simplify Health Care ETF

7.25%

Invesco Nasdaq Biotechnology ETF

6.57%

ProShares Ultra Nasdaq Biotechnology

6.13%

iShares Biotechnology ETF

5.83%

VanEck Biotech ETF

5.37%

iShares Genomics Immunology and Healthcare ETF

4.74%

First Trust NYSE Arca Biotechnology Index Fund

3.43%

First Trust NASDAQ Pharmaceuticals ETF

3.36%

iShares US Tech Breakthrough Multisector ETF

2.99%

Amplify Weight Loss Drug & Treatment ETF

占比7.43%

Simplify Health Care ETF

占比7.25%

Invesco Nasdaq Biotechnology ETF

占比6.57%

ProShares Ultra Nasdaq Biotechnology

占比6.13%

iShares Biotechnology ETF

占比5.83%

VanEck Biotech ETF

占比5.37%

iShares Genomics Immunology and Healthcare ETF

占比4.74%

First Trust NYSE Arca Biotechnology Index Fund

占比3.43%

First Trust NASDAQ Pharmaceuticals ETF

占比3.36%

iShares US Tech Breakthrough Multisector ETF

占比2.99%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

再生元制药

575.060USD

再生元制药

575.060

概览

公司

财务

分析